证券代码：600894 证券简称：广日股份 公告编号：临 2025-029 广州广日股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/3 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 日~2025 年 8 月 | 8 | 月 | 19 | 18 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | 回购价格上限 | 15.32元/股 | | | | | | 回购用途 | √减少注册资本 □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 16,802,450股 | | | | | | 实际回购股数占总股本比例 | 1.9228% | | | | | | 实际回购金额 | 19,997.45万元 | | | | | | 实际回购价格区间 | 9.67元/股~13.90元/股 | | ...

一、 回购股份的基本情况 回购方案首次披露日 2024/8/3 证券代码：600894 证券简称：广日股份 公告编号：临 2025-028 广州广日股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案实施期限 2024 年 8 月 19 日~2025 年 8 月 18 日 预计回购金额 10,000万元~20,000万元 √减少注册资本 □用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 1,612.95万股 累计已回购股数占总股本比例 1.8458% 累计已回购金额 19,297.40万元 实际回购价格区间 9.67元/股~13.90元/股 二、 回购股份的进展情况 根据《上市公司股份回购规则》和《上海证券交易所上市公司自律监管指引 第 7 号——回购股份》等相关规定，在回购股份期间，上市公司应当在每个月的 前 3 个交易日内公告截至上月末的回购进展情况。现将公司回购股份的进展情况 公告如下： 证券交易所交易系统以集 ...

证券代码：600894 证券简称：广日股份 公告编号：临 2025-028 广州广日股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上述股份回购符合公司既定的回购股份方案。 三、其他事项 的《广州广日股份有限公司第九届董事会第二十四次会议（通讯表决）决议公告》 （公告编号：临 2024-030）、《广州广日股份有限公司关于以集中竞价交易方式回 购股份并注销暨推动"提质增效重回报"的公告》（公告编号：临 2024-031）、《广 州广日股份有限公司 2024 年第二次临时股东大会决议公告》（公告编号：临 2024-036）、《广州广日股份有限公司关于以集中竞价交易方式回购股份并注销暨 推动"提质增效重回报"的回购报告书》（公告编号：临 2024-038）。 因公司实施了 2024 年半年度利润分配，根据本次回购股份方案，自 2024 年 10 月 21 日起，公司回购股份价格上限由不超过人民币 16.07 元/股（含）调整为 不超过人民币 15.32 元/股（含）。具体内容详见 ...

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]

股票简称：广日股份 股票代码：600894 编号：临 2025-027 广州广日股份有限公司 关于高级管理人员变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2 该议案已事先经第九届董事会提名委员会 2025 年第 2 次会议、第九届董事会审 计委员会 2025 年第 4 次会议审核通过。 特此公告。 广州广日股份有限公司董事会 二〇二五年五月二十七日 1 附： 巴根先生简历 巴根，男，1981 年 12 月出生，中共党员，研究生学历，工商管理硕士。历任广 州广日股份有限公司办公室临时负责人、证券部副部长、证券事务代表、证券部部 长、办公室主任、综合管理部部长、总经理助理。现任广州广日股份有限公司党委 委员、副总经理、董事会秘书、财务负责人、总法律顾问，广州塞维拉电梯轨道系 统有限公司董事、总经理，成都塞维拉电梯轨道系统有限公司董事、总经理，广日 科技发展（昆山）有限公司董事，成都广日科技有限公司董事。 广州广日股份有限公司（以下简称"公司"或"广日股份"）高级管理人员于 近日发生变动，现将有关事项公告如下： 为完 ...

Group 1 - The National Market Supervision Administration is promoting the update of old residential elevators through a new policy, ensuring safety and quality in elevator products [1] - The policy includes measures for funding sources, maintenance and update methods, and implementation timelines, which are expected to invigorate the elevator service market [1] - The focus is on encouraging elevator manufacturers to take responsibility for producing high-quality and reasonably priced elevator products [1] Group 2 - The aging of elevators in China is anticipated to drive the demand for updates, with policies and funding increasingly favoring elevator renewal [2] - As of 2023, the number of elevators in China has surpassed 10 million, indicating potential for growth in per capita elevator ownership compared to developed countries [2] - The domestic elevator manufacturers are expected to see improved business models and free cash flow, with valuations likely aligning more closely with overseas leading companies [2]

中国深圳福田区深南大道 4011 号港中旅大厦 21A-3 层、第 22A、23A、24A、25A、26A 层， 21A-3/F., 22A/F.,23A/F.,24A/F., 25A/F.,26A/F., CTS Tower, No.4011, ShenNan Road, ShenZhen, 电话（Tel.）：（86）755-83025555；传真（Fax.）：（86）755-83025068, 83025058 邮编(P.C.)：518048；网址（Website）：http://www.huashang.cn 广东华商律师事务所 关于广州广日股份有限公司 2024 年年度股东大会的 法律意见书 2025 年 5 月 广东华商律师事务所 关于广州广日股份有限公司 2024 年年度股东大会的法律意见书 致：广州广日股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）等法律、法规及规范性文件的规定， 广东华商律师事务所（以下简称"本所"）接受广州广日股份有限公司（以下简 称"公司"）的委托，指派倪小燕律师、李英杰律师出席了公司2024年年度 ...

Group 1 - The company has approved a share repurchase plan with a budget between RMB 100 million and RMB 200 million, with a maximum repurchase price of RMB 16.07 per share [1] - The repurchase will be conducted through the Shanghai Stock Exchange and the shares will be canceled, reducing the registered capital [1] - The repurchase period is set for 12 months from the approval date by the shareholders' meeting [1] Group 2 - Following the implementation of the 2024 semi-annual profit distribution, the maximum repurchase price has been adjusted to RMB 15.32 per share starting from October 21, 2024 [2] - As of April 30, 2025, the company has repurchased a total of 16.1295 million shares, representing 1.8458% of the total share capital, with a total expenditure of RMB 192.974 million [2] - The highest purchase price recorded was RMB 13.90 per share, while the lowest was RMB 9.67 per share [2] Group 3 - The company will adhere to relevant regulations during the repurchase period and will make decisions based on market conditions [3] - The company is committed to timely information disclosure regarding the progress of the share repurchase [3]

广州广日股份有限公司 2024 年年度股东大会会议资料 二○二五年五月十六日 资料目录 | 一、会议须知 | 2 | | --- | --- | | 二、会议议程 | 4 | | 三、议案一：《2024 | 年年度董事会工作报告》 5 | | 四、议案二：《2024 | 年年度监事会工作报告》 19 | | 五、议案三：《2024 | 年年度报告全文及摘要》 26 | | 六、议案四：《2024 | 年年度财务决算报告》 27 | | 七、议案五：《2025 | 年财务预算方案》 31 | | 八、议案六：《2024 | 年年度利润分配方案》 34 | | 九、议案七：《关于续聘 | 2025 年年度会计师事务所的议案》 35 | | 十、议案八：《关于公司 | 2025 年日常关联交易的议案》 36 | 1 广州广日股份有限公司 2024 年年度股东大会会议须知 为了维护广州广日股份有限公司（以下简称"公司"或"本公司"）股东的合 法权益，确保公司 2024 年年度股东大会的正常秩序和议事效率，根据《中华人民共 和国公司法》《上海证券交易所股票上市规则》《上市公司股东会规则》等法律法 规和《广州广日股份有限 ...